CERC vs. IRWD, INVA, SAVA, COLL, VRNA, TYRA, PRTA, BCYC, ELVN, and ABCL
Should you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Cassava Sciences (SAVA), Collegium Pharmaceutical (COLL), Verona Pharma (VRNA), Tyra Biosciences (TYRA), Prothena (PRTA), Bicycle Therapeutics (BCYC), Enliven Therapeutics (ELVN), and AbCellera Biologics (ABCL). These companies are all part of the "medical" sector.
Cerecor (NASDAQ:CERC) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Ironwood Pharmaceuticals received 319 more outperform votes than Cerecor when rated by MarketBeat users. However, 74.00% of users gave Cerecor an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
Ironwood Pharmaceuticals has a consensus price target of $18.40, suggesting a potential upside of 182.64%. Given Ironwood Pharmaceuticals' higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Cerecor.
Cerecor has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
62.8% of Cerecor shares are owned by institutional investors. 45.7% of Cerecor shares are owned by insiders. Comparatively, 13.1% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Ironwood Pharmaceuticals has a net margin of -254.41% compared to Cerecor's net margin of -1,194.82%. Ironwood Pharmaceuticals' return on equity of -28.45% beat Cerecor's return on equity.
Cerecor has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Cerecor is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ironwood Pharmaceuticals had 18 more articles in the media than Cerecor. MarketBeat recorded 18 mentions for Ironwood Pharmaceuticals and 0 mentions for Cerecor. Cerecor's average media sentiment score of 0.16 beat Ironwood Pharmaceuticals' score of -0.11 indicating that Cerecor is being referred to more favorably in the media.
Summary
Ironwood Pharmaceuticals beats Cerecor on 9 of the 17 factors compared between the two stocks.
Get Cerecor News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
